Roy Buchanan
Stock Analyst at JMP Securities
(1.07)
# 3,576
Out of 4,843 analysts
61
Total ratings
34.48%
Success rate
-20.1%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Reiterates: Market Outperform | $47 | $21.75 | +116.09% | 4 | May 27, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $33 → $31 | $9.78 | +216.97% | 6 | May 7, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.07 | +86.92% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.01 | +795.52% | 3 | Mar 14, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $16 | $4.48 | +257.14% | 8 | Feb 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $48.13 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $0.85 | +370.70% | 3 | Feb 11, 2025 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $21 | $5.91 | +255.63% | 12 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $0.60 | +2,236.84% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $5.99 | +450.92% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $7 | $1.51 | +363.58% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.35 | +49.25% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $572.79 | -21.79% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $12.12 | +32.01% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.77 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $2.80 | +14,900.00% | 1 | Sep 14, 2021 |
Cidara Therapeutics
May 27, 2025
Reiterates: Market Outperform
Price Target: $47
Current: $21.75
Upside: +116.09%
Dynavax Technologies
May 7, 2025
Maintains: Market Outperform
Price Target: $33 → $31
Current: $9.78
Upside: +216.97%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.07
Upside: +86.92%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.01
Upside: +795.52%
CureVac
Feb 14, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $4.48
Upside: +257.14%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $48.13
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $0.85
Upside: +370.70%
Enanta Pharmaceuticals
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $5.91
Upside: +255.63%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $0.60
Upside: +2,236.84%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $5.99
Upside: +450.92%
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $1.51
Upside: +363.58%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.35
Upside: +49.25%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $572.79
Upside: -21.79%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $12.12
Upside: +32.01%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.77
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $2.80
Upside: +14,900.00%